tirzepatide cvot SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized Tirzepatide: A Promising Drug for

As a medical student, this is one of those moments in pharmacology where you realise medicine is still full of surprises. Mohammad Junaid Rain, MBBS 2nd Year What Makes Tirzepatide Results So Remarkable

Security and banking should never be an afterthought

Kidney of rats fed on 30% chocolate

Given that PKC signaling pathway is also significantly downregulated in GPR146 knockdown cells from our phosphoproteomics study, we next tested whether GPR146 regulates adipogenesis by coupling to Gq

Falsified data disrupts this precision approach and increases the likelihood of treatment failure, forcing you to spend additional months and money on ineffective dosing

They also have trouble controlling the disease and are at a higher risk for other serious health problems such as heart disease, poor circulation in the legs and feet, nerve damage, and eye disease